EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokollOpen Access

Convergent Hybrid Ablation Versus Catheter Ablation in Patients With Persistent Atrial Fibrillation and Heart Failure: HALT AF Study Protocol and Rationale for a Multicenter Randomized Controlled Trial

Omar Ahmed iD, Elijah R Behr iD, Sarah White, Aziz Momin, Riyaz A Kaba iD

Journal of the American Heart Association · 2026

DOI: 10.1161/jaha.125.047774 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Heart Association, 2026. Verfasst von Omar Ahmed und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular and Genomics Research Institute,School of Health and Medical Sciences City St George's, University of London Cranmer Terrace London SW…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Heart Failure, Pulmonary Veins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The coexistence of persistent atrial fibrillation (AF) and heart failure with reduced left ventricular ejection fraction is associated with greater morbidity and death than either condition alone. Catheter ablation improves outcomes in selected patients, yet results in persistent AF remain unsatisfactory. Convergent hybrid ablation may offer more durable rhythm control by integrating epicardial and endocardial techniques to achieve homogeneous, transmural pulmonary vein and posterior wall isolation. However, randomized data comparing ablation strategies in patients with reduced left ventricular ejection fraction are lacking, leaving a critical evidence gap.

Methods

HALT AF (Hybrid Ablation for Atrial Fibrillation With Heart Failure) is an investigator‐initiated, multicenter, prospective, open‐label, randomized controlled trial with blinded outcome assessment. A total of 120 patients with nonparoxysmal AF, left ventricular ejection fraction 30 seconds at 12 months and off class I/III antiarrhythmic drugs, excluding a 3‐month blanking period. The primary safety end point is major adverse cardiovascular events within 30 days. Secondary end points assess cardiac remodeling, biomarkers, symptoms, and quality of life.

Conclusions

HALT AF will be the first randomized trial to compare convergent hybrid ablation and catheter ablation in patients with persistent AF and reduced left ventricular function. By enrolling only patients with reduced left ventricular ejection fraction and dilated atria and by equating lesion sets, HALT AF is designed to provide critical evidence to inform rhythm‐control strategies and guideline recommendations in this high‐risk, underrepresented population. REGISTRATION URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05411614.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationCatheter AblationHeart FailurePulmonary VeinsHumansProspective StudiesStroke VolumeVentricular Function, LeftMulticenter Studies as TopicRandomized Controlled Trials as TopicTreatment OutcomeRecurrenceTime FactorsAnti-Arrhythmia Agents

Stichwörter der Autor:innen

catheter ablationconvergent hybrid ablationheart failurehybrid ablationleft atrial appendage exclusionpersistent atrial fibrillationrandomized controlled trial

Substanzen

Anti-Arrhythmia Agents

Autor:innen und Institutionen

  • Cardiovascular and Genomics Research Institute,School of Health and Medical Sciences City St George's, University of London Cranmer Terrace London SW17 0RE UK.
  • St George's University Hospitals NHS Foundation Trust Blackshaw Road London UK.
  • Ashford and St Peter's Hospital Foundation Trust Guildford Road Surrey UK.
  • Department of Biological Sciences, Royal Holloway University of London London UK.

ORCID-Profile: Omar Ahmed, Elijah R Behr, Riyaz A Kaba

Zitieren

APA

Ahmed, O., Behr, E. R., White, S., Momin, A., & Kaba, R. A. (2026). Convergent Hybrid Ablation Versus Catheter Ablation in Patients With Persistent Atrial Fibrillation and Heart Failure: HALT AF Study Protocol and Rationale for a Multicenter Randomized Controlled Trial. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.047774

Vancouver

Ahmed O, Behr ER, White S, Momin A, Kaba RA. Convergent Hybrid Ablation Versus Catheter Ablation in Patients With Persistent Atrial Fibrillation and Heart Failure: HALT AF Study Protocol and Rationale for a Multicenter Randomized Controlled Trial. Journal of the American Heart Association. 2026. doi:10.1161/jaha.125.047774

BibTeX
@article{Ahmed2026,
  author = {Ahmed, Omar and Behr, Elijah R and White, Sarah and Momin, Aziz and Kaba, Riyaz A},
  title = {Convergent Hybrid Ablation Versus Catheter Ablation in Patients With Persistent Atrial Fibrillation and Heart Failure: HALT AF Study Protocol and Rationale for a Multicenter Randomized Controlled Trial},
  journal = {Journal of the American Heart Association},
  year = {2026},
  doi = {10.1161/jaha.125.047774}
}
Kostenlos starten →